FDA claims trial ‘manipulation’ tainted approval of ChemoCentryx drugnews2026-04-28T13:09:24+00:00April 28th, 2026|Endpoints News|
Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spendingnews2026-04-28T10:35:26+00:00April 28th, 2026|Endpoints News|
Veradermics wins at growing hair with oral Rogaine in first key test as a public companynews2026-04-27T11:00:29+00:00April 27th, 2026|Endpoints News|
Sun Pharma to buy Organon for $11.75B in major portfolio expansionnews2026-04-27T06:16:16+00:00April 27th, 2026|Endpoints News|
FDA unveils three psychedelic-focused commissioner vouchersnews2026-04-24T17:26:49+00:00April 24th, 2026|Endpoints News|
Novartis pulls Pluvicto prostate cancer label expansion filing in the EUnews2026-04-24T14:49:37+00:00April 24th, 2026|Endpoints News|
Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejectionnews2026-04-24T11:30:21+00:00April 24th, 2026|Endpoints News|
Daiichi Sankyo postpones annual results, stock dipsnews2026-04-24T09:32:42+00:00April 24th, 2026|Endpoints News|
FDA approves Regeneron’s hearing loss gene therapy Otarmeninews2026-04-23T18:53:40+00:00April 23rd, 2026|Endpoints News|
Novartis’ radioligand therapy Lutathera could soon face generic competitionnews2026-04-23T17:49:23+00:00April 23rd, 2026|Endpoints News|
